Regulatory April 26, 2023

Lipidor AB (publ) publishes annual report for 2022

STOCKHOLM, Sweden, 26th April 2023 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its annual report for the financial year 2022. The report is available on the company's website lipidor.se and in the attached pdf (in Swedish).

To read the report in full (in Swedish) click here: https://lipidor.se/arsredovisning-2022/

The information was provided for publication by Lipidor’s CEO on 26th April 2023 at 4.00 pm (CEST).

For more information, please contact
Lipidor AB (Reg. No. 556779-7500)
Ola Holmlund, CEO
Phone: +46 72 50 70 369
E-mail: ola.holmlund@lipidor.se
c/o Ekonomistubben
182 33 Danderyd

The company’s Certified Adviser is Erik Penser Bank AB.

About Lipidor AB
Lipidor AB (www.lipidor.se) is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.

Attachments
Årsredovisning 2022

Årsredovisning 2022